Allogene Therapeutics ALLO
NASDAQ ALLO
$1.62 -0.01 (-0.61%)
At close: Sep 29, 2026 · 4:00 PM EDT

Allogene Therapeutics (ALLO) Debt Ratio (2018)

Updated

Allogene Therapeutics' Debt Ratio came in at 0.32 for Q3 2018.

Analysis

Allogene Therapeutics (ALLO) Debt Ratio (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 0.24
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 0.52
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 0.42
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 0.31
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 0.00
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 0.60
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Allogene Therapeutics 562.91 Mn 562.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 0.32
API Access

Allogene Therapeutics Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=ALLO&period=max&api_key=YOUR_API_KEY